| Revenue growth | FY26 grew 10% YoY; FY27 guided at low double-digits. |
|---|---|
| Margins | Core margins 25%; US branded drag of 100-150 bps. |
| Demand visibility | Strong in Specialty, Animal Health; US branded scaling up. |
| Management confidence | High; focusing on execution-led model and specialty platform scaling. |
Growth
FY26 revenue up 10%; PAT up 16% to ₹675 Cr. Q4 India growth 4%, US generic growth positive.
Outlook
FY27 guidance: low double-digit consolidated revenue growth. Targeted R&D spend ₹750-800 Cr; Capex ₹300-350 Cr.
Risks
US pricing pressure, supply chain volatility, and initial margin drag from US branded business (Pivya).
Earnings Call filed with BSE, NSE: APLLTD. Summary written with AI assistance from the document.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹863.75
- Market cap
- ₹16,978 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 24.5×Sector 50.4×
- Promoter holding
- 69.87%+0.13% QoQ
- FII holding
- 4.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Debt & Borrowing: ₹100 Cr
Alembic Pharmaceuticals Limited has redeemed Commercial Papers (CP) worth Rs. 100 Crores. The redemption was completed on the maturity date of September 25, 2026.
- Value
- ₹100.0 Cr
Alembic Pharmaceuticals Debt & Borrowing: ₹150 Cr
Alembic Pharmaceuticals has redeemed Commercial Papers worth Rs. 150 Crore upon maturity on 23rd September 2026.
- Value
- ₹150.0 Cr
Alembic Pharmaceuticals Debt & Borrowing: ₹150 Cr
Alembic Pharmaceuticals has successfully redeemed Commercial Papers worth ₹150 Crore upon maturity. This confirms the repayment of the company's debt obligation.
- Value
- ₹150.0 Cr
Alembic Pharmaceuticals Business Update
Alembic Pharmaceuticals completed an unannounced USFDA onsite inspection at its Vadodara Bioequivalence Facility. The inspection concluded with zero Form 483 observations, a positive regulatory signal.
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.26 Cr
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in the UAE for Rs. 0.26 Crore to explore new business opportunities in pharmaceuticals.
- Value
- ₹0.26 Cr
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.25 Cr
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai to explore new business opportunities and distribution.
- Value
- ₹0.25 Cr